Fenofibrate and Crataegus oxyacantha is an effectual combo for mixed dyslipidemia

Abstract

Background: Dyslipidemia (DL) is a blood lipid disorder characterized by high cholesterol, triglyceride and low density lipoprotein with reduction of high density lipoprotein. Crataegus Oxyacantha hawthorn (COH) is used in treatment of hyperlipidemia , hypertension , angina pectoris and arrhythmia as alternative medicine . The aim of the present study was to evaluate the effect of fenofibrate alone or in combination with Crataegus Oxyacantha on lipid profile in patients with mixed dyslipidemia. Methods: A total number of 64 patients with MD on fenofibrate therapy compared to 24 healthy controls were recruited and randomized into three groups: Group A: (control, n = 24) not received any lipid-lowering agents, Group B: (fenofibrate, n = 30) received fenofibrate 200 mg/day for 10 weeks, and Group C: (combination, n = 34) received fenofibrate 200 mg/day plus C. oxycantha for 10 weeks. The estimation of lipid profile and blood pressure changes were done at baseline and following 10 weeks of therapy. Results: Following 10 weeks of C. oxycantha add on fenofibrate therapy, there was a significant reduction on total cholesterol, triglyceride, non-high-density lipoprotein-cholesterol AI, and low-density lipoprotein plasma levels compared with fenofibrate-treated patients (P